Shares of Applied Genetic Technologies Corp. opened sharply lower Tuesday and fell to a historic trough of $8.77 after the company reported slower than expected enrollment in phase I/II studies of its gene therapy candidates to treat the rare visual conditions X-linked retinoschisis (XLRS) – a program partnered with Biogen Inc. – and achromatopsia (ACHM).